Welcome to the e-CCO Library Archive!
P531
Inflammatory bowel disease and fatigue: the effect of physical activity and/or omega-3 supplementation
A. McNelly1, I. Nathan1, M. Monti2, G. Grimble3, C. Norton*4, F. Bredin5, W. Czuber-Dochan4, S. Berliner6, M. Gay6, M. Darvell6, H. Terry6, A. Forbes7
1UCL, Centre for Gastroenterology and Nutrition, London, United Kingdom, 2UCL Hospitals Foundation Trust, GI Services Division, London, United Kingdom, 3UCL, Institute of Liver and Digestive Health, London, United Kingdom, 4Kings College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom, 5Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Gastroenterology, Cambridge, United Kingdom, 6Crohn’s & Colitis UK, St Albans, United Kingdom, 7Norwich Medical School/UEA, Gastroenterology, Norwich, United Kingdom
P532
Effectiveness of balloon dilation using single balloon enteroscopy in multiple small bowel stricture
J.-S. Kim*1, Y.-S. Cho2
1Catholic University of Korea, Department of Internal Medicine, Seoul, South Korea, 2Catholic University of Korea, Department of Internal Medicine, Seoul, South Korea
P533
Assessment of 6-thioguanine nucleotide metabolite level in inflammatory bowel disease patients treated with azathioprine
K. Pavlovska*1, M. Slaninka Miceska1, P. Mishevska2, J. Tonic Ribarska3, E. Atanasovska1, I. Kikerkov1, L. Efremovska4, M. Petrushevska1
1Medical faculty, Department of preclinical and clinical pharmacology and toxicology, Skopje, Macedonia, the former Yugoslav Republic of, 2Medical faculty, Gastroenterohepatology clinic, Skopje, Macedonia, the former Yugoslav Republic of, 3Faculty of pharmacy, Skopje, Macedonia, the former Yugoslav Republic of, 4Medical faculty, Institute of physiology, Skopje, Macedonia, the former Yugoslav Republic of
P534
Risk factors for infusion reactions of infliximab in patients with Crohn’s disease
Y. Inaba*1, M. Taruishi1, M. Fujiya2, Y. Saitoh1
1Asahikawa City Hospital, Gastroenterology, Asahikawa, Japan, 2Asahikawa Medical University, Internal Medicine, Asahikawa, Japan
P535
Major nutritional diagnoses amongst outpatient inflammatory bowel disease patients
A. Ferguson*1, C. Rogge2, E. Gruber1, R. Jennings1, M. Carrie1, J. Roberts2, T. Lee2
1Illawarra Shoalhaven Local Health District, Nutrition and Dietetics, Wollongong, Australia, 2Wollongong Hospital, Gastroenterology, Wollongong, Australia
P536
Does Lémann Index reflect the quality of life in Crohn’s disease patients on treatment with biological therapy?
G. Pellegatta*1, G. Bodini1, E. Giannini1, C. De Maria1, I. Baldissarro2, V. Savarino2, E. Savarino3
1University of Genoa, Department of Gastroenterology and Internal Medicine, Genoa, Italy, 2University of Genoa, Internal Medicine Department, Genoa, Italy, 3University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Padua, Italy
P537
Weight and body composition compartments do not predict thiopurine metabolite levels
D. Holt*1, B. Strauss2, G. Moore1, 2
1Monash Health, Department of Gastroenterology & Hepatology, Clayton, Australia, 2Monash University, School of Clinical Sciences, Melbourne, Australia
P538
Hypophosphataemia after different intravenous iron infusion drugs
P. Bager*1, J. Frederik Dahlerup2
1Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark, 2Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark
P539
Clinical experience with vedolizumab in anti-TNF refractory inflammatory bowel patients
B. Christopher*1, O. Aoko2, A. O’Toole3, S. Patchett3, C. Smyth1, S. Sengupta2, R. Farrell1
1Connolly Hospital Blanchardstown, Department of Gastroenterology, Dublin, Ireland, 2Our Lady of Lourdes Hospital, Department of Gastroenterology, Drogheda, Ireland, 3Beaumont Hospital, Department of Gastroenterology, Dublin, Ireland
P540
Efficacy and safety of adalimumab in the treatment of inflammatory bowel disease in children
G. De Caro*, C. Madia, F. Gaiani, A. Fugazza, B. Bizzarri, A. Ghiselli, F. Fornaroli, F. Vincenzi, G.L. de’ Angelis
Azienda Ospedaliero Universitaria di Parma, Gastroenterologia ed Endoscopia Digestiva, Parma, Italy
P541
Cyclosporine therapy is effective in acute severe steroid-refractory ulcerative colitis
R. Iliaz1, S. Evirgen1, F. Akyuz1, B. Cavus1, B. Pinarbasi2, C. Karaca1, K. Demir1, F. Besisik1, S. Kaymakoglu*1
1Istanbul University, Department of Gastroenterology, Istanbul, Turkey, 2Liv Hospital, Department of Gastroenterology, Istanbul, Turkey
P542
Per oral antiviral treatment with valganciclovir for patients with cytomegalovirus-positive ulcerative colitis in the outpatient setting: report of 5 cases
H. Tamaki*, T. Noda, S. Arasawa, M. Izuta, A. Kubo, C. Ogawa, T. Matsunaka, M. Shibatoge
Takamatsu Red Cross Hospital, Gastroenterology, Takamatsu, Japan
P543
Cannabis use patterns in patients with IBD
T. Naftali*1, 2, L. Bar Lev Schlieder3, J. Hirsch4, I. Lish5, F. Benjaminov6, F. Konikoff6
1Meir Medical Centre, Gastroenterology, Kfar Saba, Israel, 2Tel Aviv University Sackler School of Medicine, Internal Medicine, Tel Aviv, Israel, 3Bar Ilan University, Behavioural Sciences, Tel Aviv, Israel, 4Meir Medical Centre, Department of Gastroenterology & Hepatology, Kfar Saba, Israel, 5Tel Aviv University Sackler School of Medicine, Internal Medicine, Tel Aviv, Israel, 6Tel Aviv University Sackler School of Medicine, Internal Medicine, Tel Aviv, Israel
P544
Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD
G. Fiorino1, N. Manetti*2, A. Variola3, F. Bossa4, G. Rizzuto5, L. Guidi6, G. Maconi7, S. Ghione8, L. Cantoro9, G. Lorenzon10, W. Fries11, M. L. Annunziata12, F. Costa13, M. M. Terpin14, B. Principi15, C. Cortelezzi16, L. Biancone17, A. Amato18, P. Occhipinti19, S. Mazzuoli20, S. Ardizzone21, M. Di Girolamo22, P. Alvisi23, G. Meucci24, L. Caserta25, S. Saibeni26, C. Petruzzellis27, A. Ronchetti28, M. Cappello29, F. Castiglione30, S. Danese1, A. Massella3, D. Varvara4, A. Orlando5, A. Armuzzi6, A. Massari7, P. Lionetti8, A. Kohn9, R. D’Incà10, M. Vecchi12, L. Bertani13, V. Annese on behalf of IG-IBD2, 31
1Humanitas Research Hospital and University, Gastroenterology and IBD Centre, Rozzano, Italy, 2AOU Careggi, DEA, Gastroenterology, Florence, Italy, 3Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy, 4IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy, 5Riuniti Villa Sofia - Cervello Hospital, Internal Medicine 2, Palermo, Italy, 6Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy, 7Luigi Sacco University Hospital, Gastroenterology and IBD Unit, Milan, Italy, 8Meyer Children’s Hospital, Gastroenterology and Nutrition, Florence, Italy, 9S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy, 10University of Padova, Gastroenterology, Padova, Italy, 11University of Messina, Gastroenterology, Messina, Italy, 12IRCCS Policlinico, Gastroenterology, San Donato Milanese - MI, Italy, 13AOUP, Gastroenterology, Pisa, Italy, 14AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy, 15University Bari, Gastroenterology, Bari, Italy, 16AOU di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy, 17Tor Vergata, Gastroenterology, Roma, Italy, 18Ospedale Valduce, Gastroenterology, Como, Italy, 19AOU Maggiore, Gastroenterology, Novara, Italy, 20S. Pellegrino Hospital, Gastroenterology, Trani, Italy, 21Fatebenefratelli - Oftalmico Hospital, Gastroenterology, Milano, Italy, 22University Hospital, Gastroenterology, Modena, Italy, 23Maggiore Hospital, Paediatric Department, Bologna, Italy, 24S. Giuseppe Hospital, Gastroenterology, Milano, Italy, 25IRCCS AOU S. Martino-ISTl, Gastroenterology, Genova, Italy, 26AO Hospital, Gastroenterology, Rho, Italy, 27Poliambulanza Hospital, Gastroenterology and Digestive Endoscopy, Brescia, Italy, 28AO Hospital, Internal Medicine, Lecco, Italy, 29University Hospital, Gastroenterology, Palermo, Italy, 30Federico II University, Gastroenterology, Naples, Italy, 31Italian Group for the Study of IBD, IG-IBD, Italy
P545
The effect of total and free anti-drug antibodies on infliximab pharmacokinetics between 2 drug administrations
L. Roque Ramos1, R. Barosa1, A. Nunes2, A. Regalado3, A. Vieira1, J. Freitas1, J. Demengeot3, S. Garcês*4
1Hospital Garcia de Orta, Gastroenterology, Almada, Portugal, 2Hospital Garcia de Orta, Department of Gastroenterology, Almada, Portugal, 3Instituto Gulbenkian Ciência, Oeiras, Portugal, 4Hospital Garcia de Orta, Rheumatology, Almada, Portugal
P546
Psychiatric disorder, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis
B. Jonefjäll1, 2, M. Simrén1, 3, A. Lasson4, L. Öhman1, 5, H. Strid*1, 4
1Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Department of Internal Medicine and Clinical Nutrition, Gothenburg, Sweden, 2Department of Internal Medicine, Kungälv Hospital, Kungälv, Sweden, 3University of Gothenburg Centre for Person-Centreed Care (GPCC), Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 4Department of Internal Medicine, Södra Älvsborgs Hospital, Borås, Sweden, 5Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Department of Microbiology and Immunology, Gothenburg, Sweden
P547
Effectiveness of patient education in inflammatory bowel disease
A. Berding*1, 2, C. Witte1, B. Kaltz1, R. Weiland2, A. Reusch2, H. Faller2
1German Crohn’s and Colitis Association (DCCV e.V.), Berlin, Germany, 2University of Würzburg, Department of Medical Psychology, Medical Sociology and Rehabilitation Sciences, Würzburg, Germany
P548
Anti-TNF monotherapy for Crohn’s disease: a 13-year multicentre experience
L. Peyrin-Biroulet1, J. Salleron2, J. Filippi*3, C. Reenaers4, O. Antunes3, V. Filipe1, E. Louis4, X. Hébuterne3, X. Roblin5
1Nancy University Hospital, Université de Lorraine, Nancy 1, Inserm U954 and Department of Gastroenterology, Vandoeuvre-lès-Nancy, France, 2Institut de Cancérologie de Lorraine, Department of biostatistics, Vandoeuvre les Nancy, France, 3Archet 2 Hospital, University of Nice, Gastroenterology and Nutrition Department, Nice, France, 4University of Liège, Gastroenterology Department, Liège, Belgium, 5University hospital of Saint-Etienne, Inserm, CIC1408, Gastroenterology Department, Saint-Etienne, France
P549
Adalimumab improves growth velocity in children with Crohn’s disease naïve to anti-TNF treatment
J. Martín-de-Carpi*1, E. Llerena1, M. Navalón-Rubio2, G. Pujol Muncunill1, D. Gil-Ortega2, V. Varea1, C. Sierra-Salinas3, V.M. Navas-López3, 4
1Unit for the Comprehensive Care of Paediatric Inflammatory Bowel Disease, Department of Paediatric Gastroenterology, Hepatology and Nutrition, Barcelona, Spain, 2Pediatric Gastroenterology Unit. Hospital Virgen de la Arrixaca, Murcia, Spain, 3Pediatric Gastroenterology and Nutrition Unit. Hospital Materno Infantil, Málaga, Spain, 4IBIMA, Biomedical Institute of Málaga, Málaga, Spain
P550
Patients’ perceptions about thiopurines are associated with early discontinuation in patients with inflammatory bowel diseases
M. Broekman*1, M. Coenen2, O. Klungel3, C. van Marrewijk2, G. Wanten1, L. Derijks4, S. Vermeulen2, 5, D. Wong6, A. Verbeek5, P. Hooymans6, H. Scheffer2, H.-J. Guchelaar7, M. Bouvy3, 8, D. de Jong1
1Radboud University Medical Centre, Department of Gastroenterology, Nijmegen, Netherlands, 2Radboud University Medical Centre, Department of Human Genetics, Nijmegen, Netherlands, 3Utrecht University, Departement of Pharmacoepidemiology and Clinical Pharmacotherapy, Utrecht, Netherlands, 4Maxima Medical Centre Loc. Veldhoven, Department of Gastroenterology and Hepatology, Veldhoven, Netherlands, 5Radboud University Medical Centre, Radboud Institute for Health Sciences, Nijmegen, Netherlands, 6Zuyderland Medical Centre, Department of Clinical Pharmacy, Pharmacology and Toxicology, Sittard, Netherlands, 7Leiden University Medical Centre, Department of Clinical Pharmacy and Toxicology, Leiden, Netherlands, 8SIR institute for Pharmacy Practice and Policy, Leiden, Netherlands